Overview

A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Status:
Completed
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
This long-term, continued treatment study will evaluate the long-term safety of duvelisib in patients with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.
Phase:
Phase 2
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
SecuraBio